Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Albumin · Procrit, Tachosil

Plasma-derived product · developed by Orphan Therapies Llc

Approved FDA, Oct 1942
4 Registered trials

What is Albumin?

Albumin is the main protein in blood plasma, a globular protein that binds a wide variety of ligands. It is given intravenously in studies of patients with cirrhosis, ascites, hepatic encephalopathy and postural tachycardia syndrome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Procrit, Tachosil, Waskyra, Albutein
Drug type
Plasma-derived product
Therapy area
Gastroenterology
Developer
Orphan Therapies Llc
In trials of
GRFS
FDA status
Approved as Procrit, Tachosil, Waskyra (October 21, 1942), BLA125846 · FDA label

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06812390 Phase 2 Cirrhosis Recruiting GRFS
NCT06052176 Phase 2 Cirrhosis Active not recruiting GRFS
NCT03919773 Phase 1/2 Postural Tachycardia Syndrome Completed GRFS
NCT03585257 Phase 2 Cirrhosis Completed GRFS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ascites HepaticCirrhosisCovert Hepatic EncephalopathyHepatic EncephalopathyMinimal Hepatic EncephalopathyPostural Tachycardia Syndrome

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.